Low-density lipoprotein oxidation in essential hypertension

Journal of Hypertension

Volumn 11, Issue 10, 1993, Pages 1103-1111

  Maggi, Elena ^a   Marchesi, Eugenia ^a   Ravetta, Valentina ^a   Falaschi, Francesco ^a   Finardi, Giorgio ^a   Bellomo, Giorgio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Atherosclerosis; Free radicals; Hypertension; LDL oxidation; Vitamin E

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; ANTIBODY; COPPER SULFATE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; MALE;

ADULT; ANTIBODIES; BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MIDDLE AGE; OXIDATION-REDUCTION; SUPPORT, NON-U.S. GOV'T; VITAMIN E;

EID: 0027500746     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199310000-00015     Document Type: Article

References (46)

1. Robertson WB, Strong JP: Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968, 18:538-553.
2. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP: Systolic blood pressure, arterial rigidity and risk of stroke. The Framingham Study. JAMA 1981, 245:1225-1229.
3. Moses C: Development of atherosclerosis in dogs with hypercholesterolaemia and chronic hypertension, circ Res 1954, 2:243-248.
4. Wakerlin GE, Moss WG, Kiely JP: Effect of experimental renal hypertension on experimental thiouracil-cholesterol atherosclerosis in dogs. Circ Res 1957, 5:426-434.
5. McGill HC, Frank MH, Jeer GC: Aortic lesions in hypertensive monkeys. Arch Pathol 1961, 71:96-101.
6. Hollander W: Hypertension, antihypertensive drugs and atherosclerosis. Circulation 1973, 48:1112-1127.
7. Davies PF, Remuzzi A, Gordon EJ, Dewey CF, Gimbrone MA: Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA 1986, 83:2114-2117.
8. Friedman MH, Hutchins GM, Bergeron CB, Deters OJ, Mark FF: Correlation between intimai thickness and fluid shear in human arteries. Atherosclerosis 1981, 83:425-436.
9. Kukreja RS, Datte BN, Charkravarti RN: Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis 1981, 40:291-298.
10. Campbell-Bosweix M: Lazzarini-Robertson A Effects of angio-tensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981, 35:265-276.
11. Vanhoutte PM, Lüscher TF: Serotonin and the blood vessel wall. J Hypertens 1986,(suppl 1):S29-S35.
12. Verstraete M: Platelet activation in patients with atherosclerosis of the arteries of the limbs. In Serotonin and the Cardiovascular System. Edited by Vanhoutte PM. New York: Raven Press; 1985:171-177.
13. Nakaki T, Nakayama M, Yamamoto S, Kato R: Endothelin-mediated stimulation of DNA synthesis in vascular smooth muscle cells. Biochem Biophys Res Commun 1989, 158:880-883.
14. Sarzani R, Arnaldi G, Takasaki I, Brecher P, Chobanian AV: Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart. Hypertension 1991,(suppl III):III93-III99.
15. Raines EW, Ross R: Smooth muscle cells and the pathogen-esis of the lesions of atherosclerosis. Br Heart J 1993,(suppl):S30-S37.
16. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al.: Insulin resistance in essential hypertension. TV Engl J Med 1987, 317:350-357.
17. Reaven GM: Role of abnormalities of carbohydrate and lipo-protein metabolism in the pathogenesis and clinical course of hypertension. J Cardiovasc Pharmacol 1990,(suppl V):4–7.
18. Cookson FB: The origin of foam-cells in atherosclerosis. Br J Exp Pathol 1971, 52:62.
19. Goldstein JL, Brown MS: The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977, 46:897-930.
20. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979, 76:33-37.
21. Fogelman AM, Schechter I, Saeger J, Hokom M, Child JS, Edwards PE: Malondialdehyde alteration of low-density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980, 77:2214–2218.
22. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low-density lipoproteins. Proc Natl Acad Sci USA 1981, 78:6499-6503.
23. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, et al.: Minimally modified low-density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990, 85:1260-1266.
24. Avogaro P, Bittolo BG, Cazzolato G: Presence of a modified low-density lipoprotein in humans. Arteriosclerosis 1988, 8:79-87.
25. Boyd HC, Gown AM, Wolfbauer G, Chait A: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989, 135:815-825.
26. Salonen JT, Yla-Herttuaia S, Yamamoto R, Butler S, Korpela H, Salonen R, et al.: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
27. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic Res Commun 1989, 6:67-75.
28. Dieber-Rotheneder M, Puhl W, Waeg G, Striegl G, Esterbauer H: Effect of oral supplementation with D-a-tocopherol on the vitamin E content of human low-density lipoproteins and resistance to oxidation. J Lipid Res 1991, 32:1325-1332.
29. Esterbauer H, Gebicki J, Puhl H, Jurgens G: The role of lipid peroxidation and antioxidant in oxidative modification of LDL. Free Radie Biol Med 1992, 13:341-390.
30. Jurgens G, Ashy A, Esterbauer H: Detection of new epi-topes formed upon oxidation of low-density lipoprotein, lipoprotein (a) and very-low-density lipoprotein. Biochem J 1990, 265:605-608.
31. Sies H: Oxidative stress: introductory remarks. In Oxidative Stress. Edited by Sies H. London: Academic Press; 1985:1-8.
32. Maggi E, Bellazzi R, Frattoni A, Perani G, Finardi G, Gazo A, et al.: Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1993 (in press).
33. Halliwell B: How to characterize a biological antioxidant. Free Radic Res Commun 1990, 9:1-32.
34. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH, et al.: Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11:298-306.
35. Rengstrom J, Nilsson J, Tronvall P, Landou C, Hampsten A: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992, 339:1183-1186.
36. Sharma RC, Crawford DW, Krammsh DM, Sevanian A, Jiao Q: Immunolocalization of antioxidant scavenger enzymes in early hypertensive and atherosclerotic arteries. Role of oxygen free radicals. Arterioscler Thromb 1992, 12:403-415.
37. Sagar S, Kallo JI, Kaul N, Granguly NK, Sharma BK: Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992, 111:103-108.
38. Hunter GC, Dubick MA, Keen CL, Eskelson CD: Effects of hypertension on aortic antioxidant status in human abdominal aneurysmal and occlusive disease. Proc Soc Exp Biol Med 1991, 196:273-279.
39. Jameson M, Dai FX, Lüsher T, Skopec J, Diederich A, Diederich D: Endothelium-derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993, 21:280-288.
40. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modification of low density lipoproteins that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
41. Thomas CE, Jackson LR: Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low-density lipoproteins. J Pharmacol Exp Ther 1991, 256:1182-1188.
42. Boulanger C, Hanh AWA, Lüscher TF: Oxidized low density lipoproteins release endothelin from human and porcine endothelium [abstract]. Circulation 1990,(suppl III):III225.
43. Martin-Nizard F, Houssaini F, Lessavel-Delattre S, Duriez P, Fruchart JC: Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett 1991, 293:127-130.
44. Kugiyama K, Kerns SA, Morrisset JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoprotein. Nature 1990, 344:160-162.
45. Simon BC, Cunningham LD, Cohen RA: Oxidised low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990, 86:75-79.
46. Galle J, Bassenge E, Busse R: Oxidized low density lipoproteins potentiate vasoconstriction to various agonists by direct interaction with vascular smooth muscle. Circ Res 1990, 66:1287-1293.